NCT03785873View on ClinicalTrials.gov

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 22, 2019

Primary Completion Date

November 15, 2024

Study Completion Date

November 15, 2024

Conditions
Biliary Tract Cancer
Interventions
DRUG

Nivolumab

Intravenous (IV) infusion

DRUG

Nanoliposomal-Irinotecan

Intravenous (IV) infusion

DRUG

5-Fluorouracil

Intravenous (IV) infusion

DRUG

Leucovorin

Intravenous (IV) infusion

Trial Locations (5)

48109

University of Michigan Rogel Cancer Center, Ann Arbor

49503

Cancer and Hematology Centers of Western Michigan, Grand Rapids

53705

University of Wisconsin, Madison

84132

University of Utah, Salt Lake City

98101

Virginia Mason, Seattle

Sponsors

Collaborators (2)

Ipsen
Bristol-Myers Squibb
All Listed Sponsors
collaborator

Ipsen

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

University of Michigan Rogel Cancer Center

OTHER

NCT03785873 - Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer | Biotech Hunter | Biotech Hunter